日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

在患有中重度慢性斑块状银屑病的患者中,CT-P17 与欧盟参考阿达木单抗之间反复转换的随机、双盲、活性对照、3 期互换性研究

Lebwohl, Mark G; Koo, John Y; Jaworski, Janusz; Trefler, Jakub; Daniluk, Stefan; Dudek, Anna; Baran, Wojciech; Owczarek, Witold; Kolinek, Joanna; Brzewski, Paweł; Sikora, Mariusz; Krogulec, Marek; Kim, SungHyun; Bae, YunJu; Jeon, DaBee; Choi, EunJin; Cha, JungBin; Lee, HyunJin; Choi, SuJin; Pariser, David M

Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

更正:在患有中重度慢性斑块状银屑病的患者中,CT-P17 与欧盟参考阿达木单抗之间重复转换:一项随机、双盲、活性对照、3 期互换性研究

Lebwohl, Mark G; Koo, John Y; Jaworski, Janusz; Trefler, Jakub; Daniluk, Stefan; Dudek, Anna; Baran, Wojciech; Owczarek, Witold; Kolinek, Joanna; Brzewski, Paweł; Sikora, Mariusz; Krogulec, Marek; Kim, SungHyun; Bae, YunJu; Jeon, DaBee; Choi, EunJin; Cha, JungBin; Lee, HyunJin; Choi, SuJin; Pariser, David M

Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

候选生物类似药 CT-P43 与原研药 Ustekinumab 治疗中重度斑块状银屑病的疗效和安全性:一项随机、活性对照、双盲 III 期研究的 28 周结果

Papp, Kim A; Lebwohl, Mark G; Thaçi, Diamant; Jaworski, Janusz; Kwiek, Bartlomiej; Trefler, Jakub; Dudek, Anna; Szepietowski, Jacek C; Reznichenko, Nataliya; Narbutt, Joanna; Baran, Wojciech; Kolinek, Joanna; Daniluk, Stefan; Bartnicka-Maslowska, Katarzyna; Reich, Adam; Andrashko, Yuriy; Kim, Sunghyun; Bae, Yunju; Jeon, Dabee; Jung, Jinsun; Lee, Hyunseung; Pyo, Tina; Ko, Woori